| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 14/02/2023 | 19:50 | GlobeNewswire Inc. | LIXTE BIOTECHNOLOGY HOLDINGS REPORTS NEWLY PUBLISHED INDEPENDENT PRE-CLINICAL RESEARCH | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 10/02/2023 | 12:11 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 07/02/2023 | 18:16 | GlobeNewswire Inc. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. REPORTS THAT ITS LEAD CLINICAL COMPOUND, LB-100, CAN KILL CANCER CELLS THROUGH HYPER-STIMULATION OF CELL PROLIFERATION SIGNALS IN PRE-CLINICAL MODELS | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 05/01/2023 | 17:01 | Edgar (US Regulatory) | Amended Statement of Changes in Beneficial Ownership (4/a) | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 04/01/2023 | 17:09 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 19/12/2022 | 12:03 | Edgar (US Regulatory) | Securities Registration: Employee Benefit Plan (s-8) | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 08/11/2022 | 14:31 | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 13/10/2022 | 14:30 | GlobeNewswire Inc. | LIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OF A PHASE 1B/2 RANDOMIZED TRIAL OF DOXORUBICIN +/-LB-100 IN ADVANCED SOFT TISSUE SARCOMAS TO BE CONDUCTED BY THE SPANISH SARCOMA GROUP | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 26/08/2022 | 20:51 | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (defa14a) | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 26/08/2022 | 20:50 | Edgar (US Regulatory) | Proxy Statement (definitive) (def 14a) | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 16/08/2022 | 12:06 | Edgar (US Regulatory) | Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 28/07/2022 | 22:19 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 21/06/2022 | 14:30 | GlobeNewswire Inc. | LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF BAS VAN DER BAAN, INTERNATIONALLY RECOGNIZED BIOTECH BUSINESS DEVELOPMENT EXECUTIVE, TO ITS BOARD OF DIRECTORS | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 15/06/2022 | 14:30 | GlobeNewswire Inc. | LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF PROFESSOR RENÉ BERNARDS TO ITS BOARD OF DIRECTORS | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 15/04/2022 | 00:45 | GlobeNewswire Inc. | LIXTE Biotechnology Announces the Closing of $5.8 Million Registered Direct Offering Priced At-The-Market | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 14/04/2022 | 20:54 | PR Newswire (US) | WallachBeth Capital Announces Completion of LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) $5.8 Million Registered Direct Offering | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 13/04/2022 | 15:00 | Business Wire | WestPark Capital Announces Completion of $5.8 Million Registered Direct Offering Priced At-The-Market for Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 13/04/2022 | 14:30 | PR Newswire (US) | WallachBeth Capital Announces Purchase and Sale of LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 12/04/2022 | 19:52 | GlobeNewswire Inc. | LIXTE Biotechnology Announces $5.8 Million Registered Direct Offering Priced At-The-Market | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 12/04/2022 | 14:30 | GlobeNewswire Inc. | LIXTE Biotechnology Announces Preclinical Results of its Collaboration with the Netherlands Cancer Institute, Revealing Striking Anti-Cancer Activity of LB-100 In Novel Drug Combinations | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 07/04/2022 | 12:06 | Edgar (US Regulatory) | Statement of Ownership (sc 13g) | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 22/03/2022 | 13:30 | GlobeNewswire Inc. | Inactivating Mutations in Scaffold Component of PP2A, the Target Enzyme of LIXTE Biotechnology’s Clinical Compound LB-100, are Associated with Exceptionally Long Survival of Patients with Ovarian Clear Cell Cancer Treated with Immunotherapy | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 21/03/2022 | 13:02 | Edgar (US Regulatory) | Annual Report (10-k) | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 16/03/2022 | 13:30 | GlobeNewswire Inc. | LIXTE Biotechnology Holdings, Inc. to Present at MedInvest Pharmaceutical and Biotechnology Investor Conference | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 12/01/2022 | 14:30 | GlobeNewswire Inc. | Lixte Biotechnology Announces Filing of First Patent Application Resulting from Collaboration with the Netherlands Cancer Institute and the Oncode Institute to Identify the Most Promising Drug Combinations for Lead Clinical Compound, LB-100 | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 05/01/2022 | 14:30 | GlobeNewswire Inc. | Lixte Biotechnology’s LB-100 Reported to Convert Immunologically Unresponsive (“Cold”) Tumors to Immunologically Responsive (“Hot”) Tumors | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 22/11/2021 | 15:25 | GlobeNewswire Inc. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THAT ENROLLMENT HAS RESUMED IN NATIONAL CANCER INSTITUTE’S TRIAL TO DETERMINE ABILITY OF LIXTE COMPOUND LB-100 TO ENTER RECURRENT, MALIGNANT BRAIN TUMORS | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 20/10/2021 | 15:25 | GlobeNewswire Inc. | Lixte Biotechnology to Discuss its Collaboration with Leading European Cancer Centers at the Benzinga Global Small Cap Conference on October 28 | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 13/10/2021 | 15:25 | GlobeNewswire Inc. | Lixte Biotechnology Announces Collaboration with Netherlands Cancer Institute (Amsterdam) and Oncode Institute (Utrecht) to Identify the Most Promising Drug Combinations for its Lead Clinical Compound, LB-100, for Cancer Treatment | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 20/09/2021 | 23:23 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |